Nutrigenomics and Personalised Nutrition — The Future of Football Nutrition Science

Introduction

Standard sports nutrition recommendations are population averages — carbohydrate loading, protein timing, creatine protocols — derived from studies of mean effects across populations with substantial individual variation. Nutrigenomics — the study of how genetic variation affects nutrient metabolism, requirements, and response — provides the scientific framework for personalising nutrition beyond population averages. In football, where marginal performance gains have disproportionate financial value, nutrigenomics offers the prospect of nutrition prescriptions genuinely individualised to each player’s genetic metabolic profile.

The Science

Nutrigenomics foundations: Individual variation in nutritional response arises from:

1. Variation in genes encoding metabolic enzymes — affecting how nutrients are absorbed, distributed, metabolised, and excreted
2. Variation in genes encoding nutrient transporters and receptors — affecting intracellular nutrient delivery
3. Gene-nutrient interactions — where specific nutrients modulate gene expression (nutrigenomics proper)

Clinically useful nutrigenomic variants in football:

CYP1A2 (caffeine metabolism): The primary hepatic enzyme metabolising caffeine. Two phenotypes:

• CYP1A2 AA genotype: “fast metabolisers” — caffeine cleared rapidly; peak ergogenic window shorter; potentially enhanced performance effect at standard doses
• CYP1A2 C-allele carriers (AC/CC): “slow metabolisers” — caffeine cleared slowly; higher peak plasma concentrations; increased cardiovascular side effects at standard doses; may require dose reduction

Evidence: Multiple studies show ergogenic response to caffeine is genotype-dependent; C-allele carriers may experience adverse cardiovascular effects without proportional performance benefit at doses optimal for AA genotypes.

VDR (Vitamin D receptor): Vitamin D’s intracellular actions are mediated by the vitamin D receptor (VDR). VDR polymorphisms (Fok I, Bsm I, Apa I) affect VDR expression and binding affinity — altering the biological response to a given circulating 25-OH-D concentration. VDR variant carriers may require higher serum 25-OH-D to achieve equivalent biological effects — meaning standard supplementation doses may be inadequate for certain genotypes.

MTHFR (methylenetetrahydrofolate reductase): MTHFR encodes the enzyme converting folate to its active form (5-methyltetrahydrofolate). The C677T polymorphism reduces MTHFR activity by 40% (CT heterozygote) or 70% (TT homozygote). Consequences: elevated homocysteine, impaired DNA methylation and repair, increased cardiovascular risk. TT individuals benefit disproportionately from activated folate (5-MTHF) supplementation over standard folic acid.

APOE (lipid metabolism and inflammation): APOE genotype affects cholesterol metabolism and inflammatory response. The ApoE4 allele is associated with higher LDL cholesterol from dietary saturated fat, greater inflammatory response to omega-6 fatty acids, and — notably — the Alzheimer’s disease susceptibility variant. ApoE4 carriers may have amplified risk-benefit relationships with dietary fat composition.

Omega-3 fatty acid metabolism (FADS1/FADS2): Genes encoding desaturase enzymes that convert alpha-linolenic acid (ALA) to EPA and DHA. Variant carriers have reduced conversion efficiency — they cannot adequately synthesise EPA/DHA from plant-based omega-3 sources. Direct fish oil/marine omega-3 supplementation is particularly important for FADS1/2 variant carriers.

What Research Says

Guest et al. (2018) demonstrated in Medicine & Science in Sports & Exercise that caffeine ergogenicity (10-km cycling time-trial improvement) was significantly larger in CYP1A2 AA genotype athletes than C-allele carriers — with AC/CC individuals showing no significant ergogenic effect at 4 mg/kg, while AA individuals showed consistent improvement.

Research on VDR polymorphism effects on vitamin D supplementation outcomes has demonstrated that Fok I FF genotype individuals showed greater bone density response to vitamin D supplementation than ff genotype — suggesting that identical supplementation protocols produce different biological outcomes by VDR genotype.

Research on MTHFR polymorphism epidemiology has confirmed that C677T TT homozygotes have significantly elevated cardiovascular risk that is specifically attenuated by 5-MTHF supplementation (not folic acid) — the most actionable nutrigenomic finding for supplementation personalisation.

Did You Know? One Premier League club is reported to have implemented CYP1A2 genotyping for their entire first team squad — with players identified as slow metabolisers receiving 50% reduced caffeine doses in the club’s pre-match nutrition protocol compared to fast metabolisers. The personalised caffeine protocol eliminates the anxiety, tachycardia, and gastrointestinal disturbance that slow metabolisers experience at standard doses — allowing all players to benefit from caffeine ergogenicity without adverse effects. This is one of the first commercial implementations of nutrigenomics in professional team sport.

Applied to Football

Implementing nutrigenomics in football nutrition practice:

1. CYP1A2 genotyping for caffeine protocol personalisation. A simple buccal swab test. CC/AC genotype players use 2–3 mg/kg caffeine maximum; AA genotype players use standard 3–6 mg/kg. Eliminates adverse effects in slow metabolisers.
2. MTHFR screening for supplementation optimisation. TT homozygotes should receive 5-methyltetrahydrofolate rather than standard folic acid — equal cost, substantially better bioavailability and safety in this genotype.
3. VDR-informed vitamin D dosing. Players with VDR variants may need target 25-OH-D levels of 100–125 nmol/L (rather than standard 75+ nmol/L threshold) to achieve equivalent biological effect.
4. FADS genotyping for omega-3 supplementation. FADS variant carriers need pre-formed EPA/DHA (fish oil, algal oil) — plant-based omega-3 sources (flaxseed, walnuts) are insufficient for these individuals.
5. Frame nutrigenomics as precision, not prediction. Genetic variants influence response magnitude — they do not create binary “can/cannot” responses. Nutrigenomics enables dose optimisation and risk reduction; it does not override dietary basics.

Key Takeaways

• CYP1A2 genotype determines caffeine metabolism speed — slow metabolisers need reduced doses to obtain ergogenic benefit without adverse effects
• VDR polymorphisms affect biological response to vitamin D supplementation — variant carriers may need higher target serum levels
• MTHFR C677T TT homozygotes benefit from activated folate (5-MTHF) rather than standard folic acid
• FADS1/2 variants impair ALA-to-EPA/DHA conversion — requiring direct marine omega-3 supplementation
• Nutrigenomics personalises dose optimisation — it complements, not replaces, evidence-based sports nutrition fundamentals

References

• Guest, N., Corey, P., Vescovi, J., & El-Sohemy, A. (2018). Caffeine, CYP1A2 genotype, and endurance performance in athletes. Medicine & Science in Sports & Exercise, 50(8), 1570–1578.
• Simopoulos, A. P. (2010). Genetic variants in the metabolism of omega-6 and omega-3 fatty acids: their role in the determination of nutritional requirements and chronic disease risk. Experimental Biology and Medicine, 235(7), 785–795.

Written by Hüseyin Akbulut, MSc Sport Scientist · Founder of Sporeus

Hüseyin Akbulut is the founder of Sporeus and author of THRESHOLD (EŞİK), a 540-page Turkish-language book on endurance science.

• 540pp THRESHOLD Book
• MSc Sport Sciences
• Marmara University

Full profile →